Expertise in
15
conditions

Atsushi Tanaka

Tokyo, JP 
Expertise in
15
conditions
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Atsushi Tanaka practices in Tokyo, Japan. Mr. Tanaka is highly rated in 15 conditions, according to our data. His top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Autoimmune Hepatitis, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 275 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Itabashi, 1738605, Japan
Kakogawa, 6758555, Japan
Saitama, Japan
Kyoto, 6068501, Japan
Japan
Fukuoka, 8070825, Japan
Yamagata, Japan
Osaka, Japan
Yonezawa, 9928510, Japan
Tsukuba, 3058506, Japan
Kaga, Japan
Kitakyushu, Japan
Kobe, Japan
Toyama, Japan
Hongo, 1130033, Japan
Suita, 5650871, Japan
Takasaki, 3701292, Japan
Sanda, Japan
Nagoya, 4678601, Japan
Itabashi, Japan
Ibaraki, 5670047, Japan
Health Research Course, Kagoshima, Japan
Kaga, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

275 Total Publications

Bezafibrate for primary biliary cholangitis: time to act on the evidence.
Bezafibrate for primary biliary cholangitis: time to act on the evidence.
Journal: Nature reviews. Gastroenterology & hepatology
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tanaka's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile